Literature DB >> 31776272

HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity.

Kelly M Marno1, Rebecca Pike1, Joseph M Gibbons1, Wing-Yiu Jason Lee1, Christopher E Jones1, Babatunji W Ogunkolade1, Claire Pardieu1, Alexander Bryan2, Rebecca Menhua Fu2, Gary Warnes1, Paul A Rowley3, Richard D Sloan2,4, Áine McKnight5.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr enhances viral replication in both macrophages and, to a lesser extent, cycling T cells. Virion-packaged Vpr is released in target cells shortly after entry, suggesting it is required in the early phase of infection. Previously, we described REAF (RNA-associated early-stage antiviral factor; RPRD2), a constitutively expressed protein that potently restricts HIV replication at or during reverse transcription. Here, we show that a virus without an intact vpr gene is more highly restricted by REAF and, using delivery by virus-like particles (VLPs), that Vpr alone is sufficient for REAF degradation in primary macrophages. REAF is more highly expressed in macrophages than in cycling T cells, and we detected, by coimmunoprecipitation assay, an interaction between Vpr protein and endogenous REAF. Vpr acts quickly during the early phase of replication and induces the degradation of REAF within 30 min of viral entry. Using Vpr F34I and Q65R viral mutants, we show that nuclear localization and interaction with cullin 4A-DBB1 (DCAF1) E3 ubiquitin ligase are required for REAF degradation by Vpr. In response to infection, cells upregulate REAF levels. This response is curtailed in the presence of Vpr. These findings support the hypothesis that Vpr induces the degradation of a factor, REAF, that impedes HIV infection in macrophages.IMPORTANCE For at least 30 years, it has been known that HIV-1 Vpr, a protein carried in the virion, is important for efficient infection of primary macrophages. Vpr is also a determinant of the pathogenic effects of HIV-1 in vivo A number of cellular proteins that interact with Vpr have been identified. So far, it has not been possible to associate these proteins with altered viral replication in macrophages or to explain why Vpr is carried in the virus particle. Here, we show that Vpr mitigates the antiviral effects of REAF, a protein highly expressed in primary macrophages and one that inhibits virus replication during reverse transcription. REAF is degraded by Vpr within 30 min of virus entry in a manner dependent on the nuclear localization of Vpr and its interaction with the cell's protein degradation machinery.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV; REAF; RPRD2; Vpr; innate immunity; restriction factors

Mesh:

Substances:

Year:  2020        PMID: 31776272      PMCID: PMC6997760          DOI: 10.1128/JVI.01591-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  SnapShot: antiviral restriction factors.

Authors:  Silvia F Kluge; Daniel Sauter; Frank Kirchhoff
Journal:  Cell       Date:  2015-10-22       Impact factor: 41.582

2.  Datamonkey: rapid detection of selective pressure on individual sites of codon alignments.

Authors:  Sergei L Kosakovsky Pond; Simon D W Frost
Journal:  Bioinformatics       Date:  2005-02-15       Impact factor: 6.937

3.  The Evolutionary Histories of Antiretroviral Proteins SERINC3 and SERINC5 Do Not Support an Evolutionary Arms Race in Primates.

Authors:  Ben Murrell; Thomas Vollbrecht; John Guatelli; Joel O Wertheim
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

4.  Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2.

Authors:  I P Harrison; A McKnight
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

5.  HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.

Authors:  M A Vodicka; D M Koepp; P A Silver; M Emerman
Journal:  Genes Dev       Date:  1998-01-15       Impact factor: 11.361

6.  Molecular insight into how HIV-1 Vpr protein impairs cell growth through two genetically distinct pathways.

Authors:  Claire Maudet; Matthieu Bertrand; Erwann Le Rouzic; Hichem Lahouassa; Diana Ayinde; Sébastien Nisole; Caroline Goujon; Andrea Cimarelli; Florence Margottin-Goguet; Catherine Transy
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

7.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 8.  Review: imaging technologies for flow cytometry.

Authors:  Yuanyuan Han; Yi Gu; Alex Ce Zhang; Yu-Hwa Lo
Journal:  Lab Chip       Date:  2016-11-29       Impact factor: 6.799

9.  The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.

Authors:  M E Rogel; L I Wu; M Emerman
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Promiscuous Targeting of Cellular Proteins by Vpr Drives Systems-Level Proteomic Remodeling in HIV-1 Infection.

Authors:  Edward J D Greenwood; James C Williamson; Agata Sienkiewicz; Adi Naamati; Nicholas J Matheson; Paul J Lehner
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

View more
  5 in total

1.  Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome.

Authors:  Jérémy A Ferreira Barbosa; Samantha Sparapani; Jonathan Boulais; Robert Lodge; Éric A Cohen
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

Review 2.  Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis.

Authors:  Jay Lubow; Kathleen L Collins
Journal:  Viruses       Date:  2020-07-27       Impact factor: 5.048

Review 3.  Structure, Function, and Interactions of the HIV-1 Capsid Protein.

Authors:  Eric Rossi; Megan E Meuser; Camille J Cunanan; Simon Cocklin
Journal:  Life (Basel)       Date:  2021-01-29

4.  Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.

Authors:  Catherine J Reynolds; Leo Swadling; Joseph M Gibbons; Corinna Pade; Melanie P Jensen; Mariana O Diniz; Nathalie M Schmidt; David K Butler; Oliver E Amin; Sasha N L Bailey; Sam M Murray; Franziska P Pieper; Stephen Taylor; Jessica Jones; Meleri Jones; Wing-Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James C Moon; Mahdad Noursadeghi; Daniel M Altmann; Mala K Maini; Áine McKnight; Rosemary J Boyton
Journal:  Sci Immunol       Date:  2020-12-23

Review 5.  Host Restriction Factors Modulating HIV Latency and Replication in Macrophages.

Authors:  Isabel Pagani; Pietro Demela; Silvia Ghezzi; Elisa Vicenzi; Massimo Pizzato; Guido Poli
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.